Numeric Investors’s Standard BioTools LAB Stock Holding History

Numeric Investors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-61,000	Closed	-$1.79M	–	891
2014 Q2	$1.79M	Buy	+61,000	New	+$1.95M	0.03%	343
2013 Q3	–	Sell	-14,795	Closed	-$258K	–	815
2013 Q2	$258K	Buy	+14,795	New	+$260K	0.01%	694

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Numeric Investors's LAB Position: Q3 2014 in Review

Numeric Investors sold out of Standard BioTools (LAB) in Q3 2014, closing a stake of 61,000 shares — an estimated $1.79M sold.

Numeric Investors first reported a position in LAB in Q2 2013 and held it in 2 quarters. The position peaked at $1.79M in Q2 2014. 99 funds tracked by Wall St. Rank hold LAB as of Q3 2014.

Numeric Investors reported no remaining Standard BioTools position as of Q3 2014 after selling out during the quarter.
Numeric Investors sold 61,000 Standard BioTools shares in Q3 2014, an estimated $1.79M.
Numeric Investors first reported a position in Standard BioTools in Q2 2013 and held it in 2 quarters.
Numeric Investors's Standard BioTools position peaked at $1.79M in Q2 2014.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2014.

Based on Numeric Investors's 13F filing for Q3 2014, filed 6 Nov 2014.